Bristol-Myers Squibb is crushing it in Q2 2026 with a 14% sales surge driven by top performers like Reblozyl, Breyanzi, and Camzyos—10 products hitting double-digit growth—and is raising full-year guidance. Their pipeline is equally explosive, with promising Phase 3 data for MeziKd in myeloma, encouraging antibody-drug conjugate results in solid tumors, and new studies for pumitamig and CCR8 antibodies. These innovations could redefine treatments for serious diseases, especially with iberdomide potentially becoming the first in a new myeloma class. Key trials are shifting timelines—milvexian for AFib now targets Q1 2027—and data is expected for Alzheimer’s psychosis and bipolar I studies next year. BMS is balancing today’s strong revenue with tomorrow’s breakthroughs, delivering value for patients and shareholders alike.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
